MULTI-DOMAIN PROTEIN VACCINE

1 .- 4 . (canceled)

5 . A composition comprising a fusion polypeptide, said fusion polypeptide comprising a polypeptide sequence comprising:

(a) one or more antigen polypeptides sequences, and

(b) one or more scaffold polypeptide sequences,

wherein at least one of the scaffold polypeptide sequences is connected to at least one of the one or more antigen polypeptide sequences through one or more linker sequences, and

wherein the fusion polypeptide is configured to facilitate a cleavage of the linker, a cleavage of at least one of the one or more antigen polypeptides, or presentation of at least one of the one or more antigen polypeptides.

6 . The composition of claim 5 , wherein the antigen polypeptides are cancer antigens, auto-immune antigens, or viral antigens.

7 .- 10 . (canceled)

11 . The composition of claim 5 , wherein the scaffold polypeptides are each independently selected from Titin I27, ubiquitin, Stefin A, 10FN-III, Ig-L filamin A, tenascin, fibronectin, a fragment thereof, and a variant thereof.

12 .- 126 . (canceled)

127 . A library comprising a plurality of recombinant expression constructs, wherein each expression construct of the plurality comprises:

(a) a promoter sequence;

(b) a sequence encoding a fusion polypeptide comprising:

(i) a start codon downstream of the promoter sequence;

(ii) a first polynucleotide sequence downstream of the start codon, wherein the first polynucleotide sequence comprises a distinct template polynucleotide sequence, wherein the distinct template from polynucleotide sequence (A) is derived from a sample comprising diseased cells from a subject with a disease and (B) encodes a peptide sequence of a protein encoded by the diseased cells from the subject; and

(iii) a second polynucleotide sequence downstream of the first polynucleotide sequence, wherein the second polynucleotide sequence comprises

(A) a frame check sequence and a sequence encoding one or more affinity tags downstream of the frame check sequence, or

(B) a frame check sequence comprising a sequence encoding an affinity tag.

128 . The library of claim 127 , wherein the frame check sequence operates to terminate translation of the fusion polypeptide when the distinct template polynucleotide sequence or copy thereof is out of frame with the sequence encoding an affinity tag.

129 . The library of claim 127 , wherein the frame check sequence has a formula of:

N 1 -N 2 -N 3 -N 4 -N 5 -N 6 -N 7 -N 8 -N 9 :

wherein:

each N is independently a nucleic acid selected from the group consisting of A, T, U, C and G;

each of N 1 -N 2 -N 3 and N 4 -N 5 -N 6 and N 7 -N 8 -N 9 is not a stop codon; and

each of N 2 -N 3 -N 4 and N 6 -N 7 -Ng is a stop codon.

130 . The library of claim 127 , wherein the frame check sequence encodes (a) Val-Gly-Ser; and/or (b) a linker that links the first polynucleotide sequence to the sequence encoding the affinity tag.

131 .- 132 . (canceled)

133 . The library of claim 127 , wherein the affinity tag is (a) a fragment crystallizable region (Fc region) or peptide sequence that binds to an Fc receptor, a Strep-tag, a GST-tag, a His-tag, a peptide sequence that binds to Protein A, a peptide sequence that binds to Protein G or an epitope of an antibody or binding fragment thereof; (b) non-immunogenic; and/or (c) human.

134 .- 135 . (canceled)

136 . The library of claim 127 , wherein (i) the sequence encoding the affinity tag encodes a size-enhancing polypeptide; and/or (ii) each expression construct of the library comprises a sequence encoding a size enhancing polypeptide.

137 . The library of claim 136 , wherein the sequence encoding the size enhancing polypeptide is downstream of the first polynucleotide sequence and/or at least one of the sequences encoding the size enhancing polypeptide is upstream of the distinct template polynucleotide sequence.

138 . The library of claim 136 , wherein the affinity tag is an epitope of a size enhancing polypeptide.

139 . The library of claim 136 , wherein the sequence encoding the size enhancing polypeptide encodes (a) a plurality of at least 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more size enhancing polypeptides; and/or (b) one or more linkers between two or more of the size enhancing polypeptides.

140 .- 141 . (canceled)

142 . The library of claim 139 , wherein the molecular weight of the plurality of size enhancing polypeptides is at least 15 kDa, no more than 200 kDa, and/or from 40 kDa to 80 kDa or from 50 kDa to 70 kDa.

143 .- 145 . (canceled)

146 . The library of claim 127 , wherein the subject is a human.

147 . The library of claim 127 , wherein the disease is cancer or an autoimmune disease.

148 .- 152 . (canceled)

153 . The library of claim 127 , wherein each of the distinct template polynucleotides sequences is cDNA, is derived from an RNA molecule, or is derived from genomic DNA (gDNA).

154 .- 155 . (canceled)

156 . The library of claim 127 , wherein the library comprises a plurality of distinct template polynucleotides that (a) represent at least 5% up to 100% of an exome; (b) encode at least 5% up to 100% of the peptide sequences of a proteome; and/or (c) encode peptide sequences derived from at least 5% of the proteins of a proteome.

157 .- 158 . (canceled)

159 . The library of claim 156 , wherein the exome or proteome is the exome or proteome of the diseased cells.

160 . The library of claim 127 , wherein (a) from about 5% to about 25% of polypeptides expressed from the library comprise the affinity tag; (b) from about 20% to about 40% of polypeptides expressed from the library comprise the size-enhancing polypeptide; (c) from about 50% to about 90% of polypeptides expressed from the library that comprise at least 60 amino acid residues which do not comprise the affinity tag; and/or (d) from about 85% to about 95% of the polypeptides expressed from the in frame expression constructs comprise a polypeptide that is attached to the affinity tag.

161 .- 163 . (canceled)

164 . The library of claim 127 , wherein (a) the library comprises at least 100, 1000, 10000, 100000, 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 or up to 1×10 10 distinct template polynucleotide sequences; and/or (b) the distinct template polynucleotides encode peptide sequences derived from at least 10, 50, 100, 500, 1000, 10000 or 100000 distinct proteins.

165 . (canceled)

166 . The library of claim 127 , wherein at least about 10, 100, 500, 1000, 5000 or 10000 of the distinct template polynucleotides encode a mutant peptide sequence or mRNA translation products derived from aberrantly transcribed, spliced or translated mRNA in the diseased cell or from gene rearrangements.

167 . The library of claim 166 , wherein the mutant peptide sequence is (a) a cancer-cell specific mutant peptide sequence; and/or (b) comprises a point mutation or an indel.

168 .- 171 . (canceled)

172 . A polypeptide library encoded by the library of claim 127 .

173 .- 183 . (canceled)

184 . A personalized recombinant proteome library comprising a plurality of recombinant fusion polypeptides expressed in a host cell, the plurality of recombinant fusion polypeptides comprising a plurality of polypeptide sequences encoded by a plurality of at least 10 distinct template polynucleotide sequences from a sample comprising diseased cells from a subject with a disease, and

wherein each of the polypeptide sequences encoded by the plurality of at least 10 distinct template polynucleotides comprises, in a N to C direction:

(i) a polypeptide sequence encoded by a distinct template polynucleotide of the at least 10 distinct template polynucleotide sequences, and (ii):

(A) a frame check sequence and a sequence encoding an affinity tag downstream of the frame check sequence, or

(B) a frame check sequence comprising a sequence encoding an affinity tag, and/or

(C) a size enhancing polypeptide sequence that is at least 40 kDa.

185 .- 186 . (canceled)

187 . A method of treatment comprising administering the polypeptide library of claim 172 to the subject.

188 .- 223 . (canceled)